**DOCKET NO.: O0013.70075US00**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Certificate
FEB 0 3 2005
of Correction

| | |
|---|---|
| Patent No.: | US 6,833,473 B1 |
| Issue Date: | December 21, 2004 |
| Patentee: | Markku Ahotupa |
| Serial No.: | 09/270,480 |
| Confirmation No.: | 2552 |
| Filed: | March 15, 1999 |
| For: | KITS FOR QUANTIFYING OXIDATION PARAMETERS OF LOW DENSITY LIPOPROTEINS AND USES THEREOF |
| Examiner: | Ralph J. Gitomer |
| Art Unit: | 1651 |

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 26th day of January, 2005.

June Watson

June Watson

**Mail Stop Certificate of Correction**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following document(s):

- [X] **Request for Entrance of Certificate of Correction Under 35 U.S.C. §254 & §255**
- [X] **Certificate of Correction - Form PTO-1050**
- [X] **Copy of pertinent pages from U.S. Patent No. US 6,833,473 B1**
- [X] **Return Receipt Postcard**

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned collect at (617) 646-8000, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

John R. Van Amsterdam

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. O0013.70075US00
Date: January 26, 2005
**xNDD**

4 FEB 2005

861759.1

**DOCKET NO.: O0013.70075US00**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|---|---|
| Patent No.: | US 6,833,473 B1 |
| Issue Date: | December 21, 2004 |
| Patentee: | Markku Ahotupa |
| Serial No.: | 09/270,480 |
| Confirmation No.: | 2552 |
| Filed: | March 15, 1999 |
| For: | KITS FOR QUANTIFYING OXIDATION PARAMETERS OF LOW DENSITY LIPOPROTEINS AND USES THEREOF |
| Examiner: | Ralph J. Gitomer |
| Art Unit: | 1651 |

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 26th day of January, 2005.

June Watson

June Watson

**Mail Stop Certificate of Correction**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following document(s):

**[X] Request for Entrance of Certificate of Correction Under 35 U.S.C. §254 & §255**
**[X] Certificate of Correction - Form PTO-1050**
**[X] Copy of pertinent pages from U.S. Patent No. US 6,833,473 B1**
**[X] Return Receipt Postcard**

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned collect at (617) 646-8000, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

John R. Van Amsterdam

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. O0013.70075US00
Date: January 26, 2005
xNDD

**DOCKET NO.: O0013.70075US00**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|---|---|
| Patent No.: | US 6,833,473 B1 |
| Issue Date: | December 21, 2004 |
| Patentee: | Markku Ahotupa |
| Serial No.: | 09/270,480 |
| Confirmation No.: | 2552 |
| Filed: | March 15, 1999 |
| For: | KITS FOR QUANTIFYING OXIDATION PARAMETERS OF LOW DENSITY LIPOPROTEINS AND USES THEREOF |
| Examiner: | Ralph J. Gitomer |
| Art Unit: | 1651 |

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 26th day of January, 2005.

June Watson

June Watson

**Mail Stop Certificate of Correction**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR ENTRANCE OF CERTIFICATE OF CORRECTION
UNDER 35 U.S.C. §254 and §255

Sir/Madam:

Patentee respectfully requests the correction of errors in the printing of the above-captioned patent. Specifically, claims 1, 3, 4, 5, 9, 10, 11 and 12 have typographical errors made by the Patent Office. Please correct as follows:

Claims:

In Column 13, line 33, delete "if" and replace with --in--;
line 34, delete "antioxodant" and replace with --antioxidant--;
line 40, delete "antioxodant" and replace with --antioxidant--;
line 41, after plasma, insert --sample--;
line 41, delete "2.2'" and replace with --2,2'--;
line 43, delete "The" and replace with --A--;
In Column 14, line 12, after plasma insert --sample--;
line 23, delete "2.2'" and replace with --2,2'--;
line 27, after "fraction", insert --the--;
line 30, delete "produced" and replace with --produces--;
line 34, delete "2.2'" and replace with --2,2'--;
line 36, after "wherein" insert --the--;

Patentee points out that the corrections requested do not involve change in the patent that constitutes new matter or would require reexamination, and therefore, respectfully request that a certificate of correction be issued. Patentee encloses a copy of the issued patent with the errors highlighted. Since the errors were made by the Patent Office, it is respectfully submitted that no fee is due. However, if the Examiner deems a fee necessary, the fee may be charged to Deposit Account No. 23/2825. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

For the reasons stated above, Patentee respectfully requests entrance of the enclosed Certificate of Correction.

Respectfully submitted,

John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. O0013.70075US00
Date: January 26, 2005
**xNDD**

UNITED STATES PATENT AND TRADEMARK OFFICE

# CERTIFICATE OF CORRECTION

PATENT NO. : US 6,833,473 B1

DATED : December 21, 2004

INVENTORS : Markku Ahotupa

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims:

**Claim 1:**
In Column 13, line 33, delete "if" and replace with --in--;
In Column 13, line 34, delete "antioxodant" and replace with --antioxidant--;

**Claim 3:**
In Column 13, line 40, delete "antioxodant" and replace with --antioxidant--;
In Column 13, line 41, after plasma, insert --sample--;
In Column 13, line 41, delete "2.2'" and replace with --2,2'--;

**Claim 4:**
In Column 13, line 43, delete "The" and replace with --A--;

**Claim 5:**
In Column 14, line 12, after plasma insert --sample--;

**Claim 9:**
In Column 14, line 23, delete "2.2'" and replace with --2,2'--;

**Claim 10:**
In Column 14, line 27, after "fraction," insert --the--;
In Column 14, line 30, delete "produced" and replace with --produces--;

**Claim 11:**
In Column 14, line 34, delete "2.2'" and replace with --2,2'--;

**Claim 12:**
In Column 14, line 36, after "wherein" insert --the--;

MAILING ADDRESS OF SENDER:

John R. Van Amsterdam
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211



4 FEB 2005

0.1M sodium phosphate buffer, pH 7.4, containing 0.9% of NaCl, obtained from Polysciences Inc., Warrington, Pa., USA). Chemiluminescence measurements were performed with Bio-Orbit 1251 Luminometer. Chemiluminescence in duplicate cuvettes was measured at 37° C. until a peak value for each sample was detected (see FIG. 2). Controls reactions were preformed by using in place of the LDL sample 0.1 ml of 0.1M sodium phosphate buffer, pH 8.0, containing 0.9% of NaCl and 286 mg/ml EDTA (reagent control), or 0.1 ml of 10 μmol/L trolox (6hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) in 0.1M sodium phosphate buffer, pH 8.0, containing 0.9% of NaCl and 286 mg/ml EDTA (standard). Results were calculated by the following equation:

$$20\times(\text{sample}-\text{reagent control}):(\text{standard}-\text{reagent control})\mu\text{mol/L}$$

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims. All documents referenced herein are incorporated by reference in their entirety.

I claim:

1. A kit for use in the screening of the risk for, the diagnosis, management and research of atherosclerosis and coronary heart disease comprising

a container containing a reagent for isolating LDL from a serum or plasma sample for the preparation of a LDL fraction, and

a container containing a reagent for use ~~if~~ in the determination of the ~~antioxodant~~ antioxidant potential of LDL (LDL-TRAP) in the LDL fraction.

2. The kit according to claim 1, wherein the reagent for isolating the LDL from the sample is a buffered heparin solution.

3. The kit according to claim 1, wherein the reagent for use in the determination of the ~~antioxodant~~ antioxidant potential of LDL in a serum or plasma is ~~2.2'~~ 2,2'-azobis(2-amidinopropane)HCl (ABAP).

4. ~~The~~ A kit for use in the screening of the risk for, the diagnosis management and research of atherosclerosis and coronary heart disease comprising

a container containing a reagent for isolating LDL from a serum or plasma sample for the preparation of a LDL fraction,

a container containing a reagent for separating the lipids from the LDL fraction to obtain a lipid fraction,

a container containing a reagent for use in the determination of LDL-BDC in the lipid fraction, and

a container containing a reagent for use in the determination of LDL-TRAP in the LDL fraction.

5. The kit according to claim 4, wherein the reagent for isolating the LDL from the serum or plasma is a buffered heparin solution.

6. The kit according to claim 4, wherein the reagent for separating the lipid is a chloroform-methanol solution.

7. The kit according to claim 4, wherein the reagent for use in the determination of LDL-BDC in the lipid fraction is an organic solvent.

8. The kit according to claim 7, wherein the reagent for use in the determination of LDL-BDC in the lipid fraction is a cyclohexane.

9. The kit according to claim 4, wherein the reagent for use in the determination of the antioxidant potential of LDL is the sample is ~~2.2'~~ 2,2'-azobis(2-amidinopropane)HCl (ABAP).

10. A kit for use in determining antioxidant potential of a LDL fraction of blood serum or plasma, comprising

a first container for extracting lipids from the LDL fraction, first container containing a solvent which extracts lipids from a LDL fraction; and

a second container containing an amount of a compound which ~~produces~~ peroxyl radicals sufficient to induces lipid peroxidation of the LDL fraction.

11. The kit according to claim 10, wherein the compound in the second container is ~~2.2'~~ 2,2'-azobis(2-amidinopropane) HCl (ABAP).

12. The kit of claim 11, wherein ABAP is a powder and further comprising a third container containing a solution for suspension of the ABAP.

13. The kit of claim 11, further comprising a third container containing a compound which enhances luminescence.

14. The kit of claim 13, wherein the compound which enhances luminescence is luminol.

* * * * *

4 FEB 2005